Retia Medical, LLC
Retia Medical aims to advance the use of cardiac output (CO) monitoring to improve patient care by providing members of the critical care team with a more accurate, easy-to-use, and affordable hemodynamic monitor that supports confident, data-driven decisions. Retia brings together industry-leading expertise in physiology, signal processing and computational algorithms to engineer innovative monitoring solutions that give clinicians up-to-the minute data that they can rely on to make informed patient care decisions. Additionally, Retia is committed to giving more clinicians access to CO monitoring by reducing the cost and inconvenience that limit the use of traditional CO technologies to the most high-risk patients. ). The initial interest for this technology is the ICU and operating rooms. Approximately 15 million surgical patients and 3 million intensive care patients worldwide could benefit from this technology.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Monitoring
- Market Focus:
- Globally (various continents)
About us
Retia’s highly accurate, easy-to-use and cost-effective lead product, the Argos Cardiac Output Monitor equipped with the company’s proprietary Multi-Beat Analysis (MBA™) algorithm, guarantees superior CO monitoring performance, quality, reliability, and compatibility for enhanced hemodynamic management. Retia is also developing new algorithms to aid in detecting, diagnosing and treating shock. These include algorithms for calculating ejection fraction and end diastolic volume from arterial lines; predicting and detecting hypotension via non-invasive blood pressure; and calculating continuous CO and left atrial pressure from pulmonary artery pressure waveforms.
Based in Valhalla, NY, Retia’s technology was developed at Michigan State University and Massachusetts Institute of Technology and validated through extensive tests in animals and humans. With the support of a strong advisory board comprised of industry and clinical experts, Retia received FDA 510(k) clearance and launched this product in December 2018, which will help revolutionize the care of the most at-risk patients.